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LETTER TO THE EDITOR Open Access
Serum periostin does not reflect type 2-
driven inflammation in COPD
O. A. Carpaij1,2*, F. O. W. Muntinghe2, M. B. Wagenaar2, J. W. Habing2, W. Timens1,3, H. A. M. Kerstjens1,2,
M. C. Nawijn1,3, L. I. Z. Kunz4, P. S. Hiemstra4, G. W. Tew5, C. T. J. Holweg5, C. A. Brandsma1,3
and M. van den Berge1,2
Abstract
Although Th2 driven inflammation is present in COPD, it is not clearly elucidated which COPD patients are affected.
Since periostin is associated with Th2 driven inflammation and inhaled corticosteroid (ICS)-response in asthma, it
could function as a biomarker in COPD. The aim of this study was to analyze if serum periostin is elevated in COPD
compared to healthy controls, if it is affected by smoking status, if it is linked to inflammatory cell counts in blood,
sputum and endobronchial biopsies, and if periostin can predict ICS-response in COPD patients.
Serum periostin levels were measured using Elecsys Periostin immunoassay. Correlations between periostin and
inflammatory cell count in blood, sputum and endobronchial biopsies were analyzed. Additionally, the correlation
between serum periostin levels and treatment responsiveness after 6 and 30 months was assessed using i.e.
ΔFEV1% predicted, ΔCCQ score and ΔRV/TLC ratio. Forty-five COPD smokers, 25 COPD past-smokers, 22 healthy
smokers and 23 healthy never-smokers were included. Linear regression analysis of serum periostin showed positive
correlations age (B = 0.02, 95%CI 0.01–0.03) and FEV1% predicted (B = 0.01, 95%CI 0.01–0.02) in healthy smokers, but
not in COPD patients In conclusion, COPD -smokers and -past-smokers have significantly higher periostin levels
compared to healthy smokers, yet periostin is not suitable as a biomarker for Th2-driven inflammation or ICS-
responsiveness in COPD.
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To the editor
Recent research suggests that type 2-driven eosinophilic in-
flammation is present in a subset of COPD patients [1].
This is important as it may predict responsiveness to
anti-inflammatory treatment with inhaled corticosteroids
(ICS) and possibly also targeted therapies like interleukin-5
monoclonal antibodies [2].
Periostin is an extracellular matrix protein that has
been proposed as biomarker for type 2-driven inflamma-
tion [3]. While the majority of studies so far investigated
the clinical implication of circulating periostin levels in
asthma, data regarding COPD is scarce [3–5].
The aim of this study was to investigate whether
serum periostin levels are different in COPD patients
compared to healthy controls and whether they are af-
fected by smoking. In addition, we assessed to what ex-
tent serum periostin levels reflect inflammatory cell
counts in blood, sputum and endobronchial biopsies in
COPD and whether serum periostin levels predict airway
wall remodeling and ICS responsiveness following treat-
ment of 6 or 30 months.
We included COPD patients who participated in the
Groningen and Leiden Universities study of Corticoste-
roids in Obstructive Lung Disease (GLUCOLD) as de-
scribed previously [6, 7]. Patients were 45–75 years,
Caucasian, had an FEV1/FVC ratio < 70%, ≥10 pack
years, and no history of asthma. Subjects were ran-
domly assigned to receive long-term ICS with or with-
out an added long-acting beta2-agonist (LABA) or
placebo-treatment.
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Healthy subjects were 40–75 years, Caucasian, had an
FEV1/FVC ratio ≥ 70% and PC20 methacholine >
19.6 mg/mL [8], and were divided into smokers (i.e.
smoking ≥10 cigarettes/day and ≥ 10 pack years) and
never-smokers.
From the previous studies [6, 8], COPD patients and
healthy controls underwent the following tests: pulmonary
function tests, peripheral blood tests, sputum induction, a
bronchoscopy and filled in questionnaires. From the
present study, serum periostin levels were measured using
the clinical trial version of the Elecsys® Periostin immuno-
assay (Roche Diagnostics, Penzberg Germany) [9].
The local ethics committee approved both study pro-
tocols and all subjects gave written informed consent.
First, demographic and clinical variables in COPD pa-
tients and healthy controls were compared using inde-
pendent sample t-tests for normally distributed data,
Mann-Whitney U tests for non-normally distributed
data and chi-square tests for categorical variables. To as-
sess possible confounders of log2 transformed periostin
values, a univariate analysis was performed. Next, a lin-
ear regression model was used to assess the association
between serum periostin levels and inflammatory cell
counts in blood, sputum and endobronchial biopsies at
baseline, with correction for significant confounders. A
linear regression was used to analyze serum periostin
levels in association with ICS treatment responsiveness
(i.e. change in FEV1, Clinical COPD Questionnaire
(CCQ)-total score and RV/TLC after 6 and 30 months
treatment) and airway wall remodelling in COPD pa-
tients. Airway wall remodeling in endobronchial biopsies
was measured by dividing immunohistochemical stained
area for elastic fibers, versican, decorin, collagen I and
III by the total selected lamina propria area as described
previously [7].
Of the 114 COPD patients enrolled in GLUCOLD, 70
subjects had available measured serum periostin level at
baseline. COPD smokers (n = 45/70) were 60.3 (SD ±
7.9) years, smoked 46.7 (SD ± 19.8) packyears, had a %
FEV1 predicted of 63.8% (SD ± 7.8%) and a serum peri-
ostin level of 51.8 ng/ml [IQR 48.4–59.8 ng/ml]. COPD
former-smokers (n = 25/70) had a mean age of 64.7 (SD
± 7.3), smoked 45.6 (SD ± 27.7) pack years, % FEV1 pre-
dicted of 60.9% (SD ± 10.5%) and a serum periostin level
of 54.8 ng/ml [IQR 47.8–62.2 ng/ml]. The healthy
smokers (n = 22) were 52.1 (SD ± 7.5) years, smoked 29.0
(SD ± 11.6) pack years, had a mean % FEV1 predicted of
104.0% (SD ± 11.2%) and a serum periostin of 44.6 ng/
ml [IQR 39.8–51.2 ng/ml]. The healthy never-smokers
(n = 23) had a mean age of 58.4 (SD ± 9.1), mean FEV1%
predicted of 108.6% (SD ± 13.9%) and serum periostin of
49.7 ng/ml [IQR 41.8–54.7 ng/ml] (see Additional file 1).
Serum periostin was significantly higher in COPD
smokers (P = 0.009) as well as COPD former-smokers
(P = 0.001) compared to the healthy smoker-group.
Serum periostin was similar between COPD smokers
and COPD former-smokers. In agreement with our
findings, Golpe et al. also found higher significantly
periostin levels in both tobacco smoke- as well as bio-
mass cooking-induced COPD compared to healthy con-
trols [10]. However, the latter study only investigated
never-smoking controls and did not include matched
current- and former-smoking controls. In addition, they
used another method to analyse serum periostin and
found undetectable levels in the never-smoking con-
trols. Two other studies did not find a difference in
serum periostin levels between COPD and predomin-
antly never-smoker controls [4, 5].
In our study, healthy never-smokers tended to have
higher periostin levels compared to healthy smokers (P
= 0.08), which was also seen in other studies [11, 12].
Caswell-Smith et al. saw a significantly higher periostin
level in 312 never-smokers compared to 22 healthy
smokers [12]. Taking together, there is evidence that
current smoking is associated with lower serum perios-
tin levels in healthy controls. It is interesting to note that
studies from our laboratories using cultured human
bronchial epithelial cells did not provide evidence for in-
duction of epithelial periostin expression by cigarette
smoke exposure, an even showed that type 2 cytokine
(IL-13) induced periostin expression was suppressed by
cigarette smoke [13].
Next, we assessed the correlations between serum perios-
tin levels and clinical and inflammatory characteristics in
COPD patients and healthy smokers and never-smokers.
Results of the univariate and linear regression analyses are
presented in Table 1. In COPD patients, no correlation was
found between periostin and age, lung function and inflam-
matory cell counts in blood, sputum and biopsies. In the
healthy smoker-group, periostin levels were significantly
positively associated with age (B = 0.02, 95%CI 0.01–0.03)
and post-bronchodilator FEV1% predicted (B = 0.01, 95%CI
0.01–0.02). After adjusting the data for the last mentioned
possible confounders, no further correlations were found in
the healthy smokers. In the healthy never-smoker group,
periostin was associated with higher percentages of sputum
lymphocytes (B = 0.3, 95%CI 0.1–0.5). Our finding is that
serum periostin levels do not reflect type 2-driven inflam-
mation in COPD, is in agreement with the findings of Kon-
stantelou et al. who measured serum periostin in 155
COPD patients admitted for a COPD exacerbation and
found no correlations with severity of airflow obstruction
or eosinophilic inflammation measured in blood [14].
To our analysis, baseline periostin levels did not predict
ICS responsiveness in COPD; there was no correlation
with improvement in lung function, decrease in hyp-
erinflation or CCQ-total score after either 6 or 30 months
of ICS-treatment. Studies investigating periostin as
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Table 1 Regression analysis of baseline log2 transformed periostin with baseline characteristics in COPD-patients, healthy smokers
and never-smokers
ICS naive COPD Healthy smoker Healthy never-smoker
(n = 70) (n = 22) (n = 23)
Univariate regression Bexp (95% CI) Bexp (95% CI) Bexp (95% CI)
Sex, male (%) 4.7 (0.6–36.9) 0.2 (0.004–11.4) 1.9 (0.1–29.7)
Smokers (%) 0.4 (0.1–2.0) NA NA
Linear regression B (95% CI) B (95% CI) B (95% CI)
Packyears (years) 7.0 × 10− 5 (− 0.004–0.004) NA NA
Age (years) 0.01 (− 0.003–0.2) 0.02 (0.01–0.03) * 0.01 (− 0.01–0.03)
BMI, (kg/m2) 0.2 (− 0.1–0.1) −0.1 (− 0.3–0.1) 0.04 (− 0.1–0.2)
% predicted FEV1 post-bronchodilator −0.03 (− 0.01–0.01) 0.01 (0.04–0.02) * 0.01 (− 0.01–0.02)
FEV1/IVC ratio (%) 0.01 (− 0.004–0.01) 0.0 (− 0.02–0.02) 0.013 (− 0.02–0.04)
RV/TLC ratio (%) 0.003 (− 0.01–0.01) 0.02 (− 0.02–0.1) 0.02 (− 0.01–0.04)
Fractional exhaled Nitric Oxide (ppb) 0.001 (− 0.01–0.01) NA NA
Total IgE (IU/L) 4.2 × 10− 5 (0.0–0.0) NA NA
PC20 methacholin threshold (mg/ml)
# 0.1 (− 0.03–0.1) NA NA
Blood eosinophils (%) # 0.1 (− 0.03–0.1) − 0.07 (− 0.2–0.1) 0.03 (− 0.2–0.2)
Blood basophils (%) # 0.04 (− 0.04–0.1) −0.1 (− 0.2–0.1) 0.1 (− 0.1–0.2)
Blood neutrophils (%) −0.001 (− 0.01–0.01) − 0.004 (− 0.02–0.01) −0.02 (− 0.04–0.01)
Blood monocytes (%) 0.03 (− 0.01–0.1) 0.01 (− 0.1–0.1) 0.02 (− 0.08–0.1)
Blood lymphocytes (%) −0.003 (− 0.01–0.01) 0.01 (− 0.01–0.02) 0.02 (− 0.01–0.04)
Sputum eosinophils (%) − 0.01 (− 0.1–0.04) −0.01 (− 0.2–0.1) 0.1 (− 0.1–0.2)
Sputum neutrophils (%) −7.7 × 10− 6 (− 0.01–0.01) 0.002 (− 0.006–0.01) −0.004 (− 0.01–0.01)
Sputum macrophages (%) −0.001 (− 0.01–0.01) −0.002 (− 0.01–0.01) 0.001 (− 0.01–0.01)
Sputum lymphocytes (%) 0.1 (− 0.01–0.1) 0.108 (− 0.2–0.4) 0.3 (0.1–0.5) *
Biopsy eosinophils (count/0.1mm2) −0.001 (− 0.003–0.002) −0.03 (− 0.1–0.06) 0.01 (− 0.03–0.04)
Biopsy neutrophils (count/0.1mm2) # 0.02 (− 0.03–0.08) −0.002 (− 0.07–0.07) −0.08 (− 0.2–0.04)
Biopsy macrophages (count/0.1mm2) # 0.045 (− 0.03–0.1) −0.03 (− 0.1–0.1) 0.03 (− 0.1–0.1)
Biopsy lymphocytes (count/0.1mm2) 0.000 (− 0.001–0.001) −0.01 (− 0.01–0.002) −0.02 (− 0.1–0.1)
Biopsy elastic fibers area (%) 0.002 (− 0.01–0.01) NA NA
Biopsy elastic fibers density (gray value) 0.002 (− 0.01–0.02) NA NA
Biopsy versican area (%) −0.001 (− 0.01–0.01) NA NA
Biopsy versican density (gray value) −0.01 (− 0.03–0.01) NA NA
Biopsy decorin area (%) − 8.15 × 10− 6 (< 0.001 – < 0.001) NA NA
Biopsy decorin density (gray value) −0.003 (− 0.1–0.045) NA NA
Biopsy collagen I area (%) −0.003 (− 0.01–0.01) NA NA
Biopsy collagen I density (gray value) 0.003 (− 0.02–0.03) NA NA
Biopsy collagen III area (%) −0.004 (− 0.01–0.03) NA NA
Biopsy collagen III density (gray value) −0.01 (− 0.02–0.01) NA NA
Biopsy mean number of ki-67 pos. Cells (count/0.1mm2) 0.001 (− 0.001–0.003) NA NA
Biopsy PAS pos. Area epithelium (%) 0.000 (− 0.01–0.01) NA NA
Biopsy EGFR pos. Epithelium area (%) 0.002 (− 0.01–0.01) NA NA
Biopsy EGFR pos. Epithelium density (gray value) 5.8 × 10− 6 (< 0.001 – < 0.001) NA NA
#: log2 transformed variable, *: statistically significant P < 0.05, BMI: Body Mass Index. NA: not available, area (%): the percentage stained area for a specific extracellular
matrix component was calculated dividing the stained area by the total selected area, density (gray value): staining intensity was analyzed by densitometry (weighted
mean per biopsy) and presented as gray value (black: gray value: 0, white: gray value: 255)
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biomarker for ICS treatment in COPD patients are lim-
ited. In this context, the findings of Park et al. are of inter-
est [15]. They studied 130 COPD patients before and after
three months of ICS/LABA treatment and found that a
combination of high plasma periostin levels (> 23 ng/mL)
and high blood eosinophil counts (> 260/μL) could predict
a better improvement in FEV1. However, it is important to
note that patients with this combination of high periostin
and blood eosinophils already had a higher bronchodilator
response at baseline and therefore the better improvement
might have been due to the LABA component alone.
Finally, no correlation was detected between baseline peri-
ostin and change in extracellular matrix (lamina propria
components stained area or density) after 30 months on ICS
or placebo treated COPD patients (see Additional file 1).
Conclusion
In conclusion, we show that smoking and former-smoking
COPD patients have significantly higher serum periostin
values compared to healthy smoking controls, yet perios-
tin levels do not reflect type 2-driven inflammation, airway
remodeling, or ICS treatment responsiveness and is thus
not a good biomarker in this population.
Additional file
Additional file 1: Supplementary Tables. (DOCX 95 kb)
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